Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chief scientific officer Robert Lanza, M.D., is featured on the “TOP 50 Global Stem Cell Influencers” list from Terrapinn’s life sciences division, TotalBiopharma (“World Stem Cells & Regenerative Medicine Congress 2013”). The list features the most influential people in the global stem cell and cell therapy field, including world renowned academics, industry players, and governmental officials. Dr. Lanza was among the top four on the list, alongside the University of Wisconsin’s Dr. James Thomson, known as the first scientist to derive human embryonic stem cells (in 1998) and for his work with induced pluripotent stem (iPS) cells; and Kyoto University’s Dr. Shinya Yamanaka, co-winner of the 2012 Nobel Prize for Physiology or Medicine for his work with iPS cells, and a winner of the inaugural $3 million Breakthrough Prize in Life Sciences earlier this year. Terrapinn, the global firm sponsoring the inaugural list, refers to it as being similar to the “Forbes [Celebrity] 100, but for stem cells.” It is the result of a global survey of the stem cell community, which yielded thousands of votes. The 50 personalities were picked based on their career achievements whether this was groundbreaking discovery and research, innovation, or lifetime dedication. More information is available here. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2012. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.